Department of Microbiology, College of Medicine, University of Maisan, Maisan, Iraq.
Arch Razi Inst. 2022 Feb 28;77(1):205-211. doi: 10.22092/ARI.2021.356992.1956. eCollection 2022 Feb.
In carcinogenesis, KRAS is an essential oncogene that plays a key function. The polymorphism of rs61764370 is a candidate for cancer susceptibility in KRAS3' untranslated region. The current study aimed to determine the role and impact of the KRAS gene polymorphism (rs61764370 T>G) on the risk of ovarian cancer development in the Iraqi population. In total, 84 ovarian cancer patients and 28 ovarian benign tumors were involved in a case-control study. DNA extraction from the formalin-fixed/paraffin-embedded tissues, followed by the sequencing of PCR products was carried out in genetic analysis for the detection of the KRAS polymorphism (rs61764370 T>G). The results showed that the frequencies of the KRAS gene polymorphism (rs61764370) in ovarian cancer patients were 78 (92.85%) and 6 (7.15%) with genotypes homozygote TT and heterozygote TG, respectively. These corresponding values in patients with benign ovarian tumors were 25 (89.3%) and 3 (10.7%) with homozygote TT and heterozygote TG, respectively. None of the patients either with malignant or benign tumors have been detected with homozygote genotype GG. Genotype frequency of the TT and TG showed that the heterozygote TT genotype vs. TG and T allele vs. G allele were more frequent in malignant and benign tumors (P≤0.01). Statistically, there was no association between the KRAS polymorphism and the clinical characteristics of ovarian cancer patients, such as age, family history, menopause, histological type, tumor size, or tumor stage. In conclusion, a significant association was found between rs61764370 and the risk of ovarian cancer in the Iraqi population, particularly those with genotypes homozygote TT. On the other hand, genotypes had no relationship with any of the clinical characteristics of ovarian cancer patients. Additional well-designed studies with larger sample sizes are recommended to validate the precise role of KRAS LCS6 variations in ovarian cancer risk.
在致癌作用中，KRAS 是一种重要的癌基因，发挥着关键作用。rs61764370 的多态性是 KRAS3'非翻译区癌症易感性的候选基因。本研究旨在确定 KRAS 基因多态性（rs61764370 T>G）在伊拉克人群卵巢癌发病风险中的作用和影响。共有 84 例卵巢癌患者和 28 例卵巢良性肿瘤患者参与了病例对照研究。通过聚合酶链反应（PCR）产物的测序，从福尔马林固定/石蜡包埋组织中提取 DNA，进行基因分析，以检测 KRAS 多态性（rs61764370 T>G）。结果显示，卵巢癌患者 KRAS 基因多态性（rs61764370）的频率分别为 78 例（92.85%）和 6 例（7.15%），基因型分别为纯合子 TT 和杂合子 TG。在卵巢良性肿瘤患者中，相应值分别为 25 例（89.3%）和 3 例（10.7%），基因型分别为纯合子 TT 和杂合子 TG。在恶性或良性肿瘤患者中均未检测到纯合子基因型 GG。TT 和 TG 基因型频率显示，杂合子 TT 基因型与 TG 基因型和 T 等位基因与 G 等位基因在恶性和良性肿瘤中更为常见（P≤0.01）。统计学分析显示，KRAS 多态性与卵巢癌患者的临床特征如年龄、家族史、绝经、组织学类型、肿瘤大小或肿瘤分期之间无相关性。总之，rs61764370 与伊拉克人群卵巢癌的发生风险之间存在显著相关性，特别是在纯合子 TT 基因型中。另一方面，基因型与卵巢癌患者的任何临床特征均无关系。建议开展更多设计合理、样本量更大的研究，以验证 KRAS LCS6 变异在卵巢癌风险中的精确作用。
